@article{SturmHessWeibeletal.2012,
  author    = {Sturm, Julia B. and Hess, Michael and Weibel, Stephanie and Chen, Nanhei G. and Yu, Yong A. and Zhang, Quian and Donat, Ulrike and Reiss, Cora and Gambaryan, Stepan and Krohne, Georg and Stritzker, Jochen and Szalay, Aladar A.},
  title     = {Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-75224},
  year      = {2012},
  abstract  = {Background: Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic. Methods: Here, we describe a novel approach to optimize combination therapy of oncolytic virus and chemotherapy utilizing virus-encoding hyper-IL-6, GLV-1h90, to reduce chemotherapy-associated side effects. Results: We showed that the hyper-IL-6 cytokine was successfully produced by GLV-1h90 and was functional both in cell culture as well as in tumor-bearing animals, in which the cytokine-producing vaccinia virus strain was well tolerated. When combined with the chemotherapeutic mitomycin C, the anti-tumor effect of the oncolytic virotherapy was significantly enhanced. Moreover, hyper-IL-6 expression greatly reduced the time interval during which the mice suffered from chemotherapy-induced thrombocytopenia. Conclusion: Therefore, future clinical application would benefit from careful investigation of additional cytokine treatment to reduce chemotherapy-induced side effects.},
  subject      = {Biologie},
  language  = {en}
}
@article{HailerGrunewaldOrthetal.2014,
  author    = {Hailer, Amelie and Grunewald, Thomas G. P. and Orth, Martin and Reiss, Cora and Kneitz, Burkhard and Spahn, Martin and Butt, Elke},
  title     = {Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration},
  series = {Oncotarget},
  volume    = {5},
  journal   = {Oncotarget},
  number    = {12},
  issn      = {1949-2553},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120540},
  pages     = {4144-53},
  year      = {2014},
  abstract  = {Several studies have linked overexpression of the LIM and SH3 domain protein 1 (LASP1) to progression of breast, colon, liver, and bladder cancer. However, its expression pattern and role in human prostate cancer (PCa) remained largely undefined. Analysis of published microarray data revealed a significant overexpression of LASP1 in PCa metastases compared to parental primary tumors and normal prostate epithelial cells. Subsequent gene-set enrichment analysis comparing LASP1-high and -low PCa identified an association of LASP1 with genes involved in locomotory behavior and chemokine signaling. These bioinformatic predictions were confirmed in vitro as the inducible short hairpin RNA-mediated LASP1 knockdown impaired migration and proliferation in LNCaP prostate cancer cells. By immunohistochemical staining and semi-quantitative image analysis of whole tissue sections we found an enhanced expression of LASP1 in primary PCa and lymph node metastases over benign prostatic hyperplasia. Strong cytosolic and nuclear LASP1 immunoreactivity correlated with PSA progression. Conversely, qRT-PCR analyses for mir-203, which is a known translational suppressor of LASP1 in matched RNA samples revealed an inverse correlation of LASP1 protein and mir-203 expression. Collectively, our results suggest that loss of mir-203 expression and thus uncontrolled LASP1 overexpression might drive progression of PCa.},
  language  = {en}
}
@phdthesis{Reiss2010,
  author    = {Reiß, Cora},
  title     = {Einfluss von Defekten des Mismatch Reparatur Proteins MLH1 (Mut L Homolog 1) auf Fertilit{\"a}t und Tumorgenese im Mausmodell},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-53626},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Mutationen im humanen DNA Mismatch-Reparatur (MMR) Gens Mlh1 sind mit dem erblichen, nicht-polyp{\"o}sen Kolonkarzinom (Lynch Syndrom, HNPCC) und einem signifikanten Anteil sporadischer kolorektaler Tumore assoziiert. Zudem konnten MMR Defekte in sporadischen und erblichen Lymphom Erkrankungen beschrieben werden. In Zellen resultiert die Inaktivierung des Mlh1 Gens in der Akkumulation von somatischen Mutationen im Genom und einer erh{\"o}hten Resistenz gegen{\"u}ber den genotoxischen Effekten einer Vielzahl von DNA sch{\"a}digenden Agenzien. M{\"a}use, die ein Null Allel f{\"u}r das MMR Gen Mlh1 tragen zeigen einen starken Tumorpr{\"a}dispositions Ph{\"a}notyp. Sie entwickeln vorrangig B- und T-Zell Lymphome und mit geringerer Haufigkeit gastrointestinale Tumore. Zus{\"a}tzlich sind Mlh1-/- M{\"a}use durch einen meiotischen Ph{\"a}notyp charakterisiert, der zu Sterilit{\"a}ten in beiden Geschlechtern f{\"u}hrt. Um die Effekte von Mlh1 missense Mutationen auf die Tumoranf{\"a}lligkeit zu untersuchen, erzeugten wir eine Mauslinie, die die h{\"a}ufig in HNPCC Patienten beschriebene MLH1G67R Mutation tragen, die in einer der ATP Bindungs-Dom{\"a}nen von MLH1 lokalisiert ist. Auch wenn die MLH1G67R Mutation in homozygot mutanten M{\"a}usen in einer DNA Reparatur Defizienz resultierte hatte sie keinen Effekt auf die MMR vermittelte zellul{\"a}re Antwort auf DNA Sch{\"a}den. Hierzu geh{\"o}rte die apoptotische Antwort von Epithelzellen der intestinalen Mucosa auf Cisplatin, die in Mlh1-/- M{\"a}usen defektiv jedoch in Mlh1G67R/G67R M{\"a}usen normal ausfiel. Mlh1G67R/G67R mutante M{\"a}use zeigten wie Mlh1-/- Tiere einen starken Tumorpr{\"a}dispositions Ph{\"a}notyp. Sie entwickelten jedoch im Vergleich zu Mlh1-/- Tieren signifikant weniger gastrointestinale Tumore, was darauf hinweist, dass Mlh1 missense Mutationen die Tumor supprimierende MMR Funktion in einer Gewebs-spezifischen Weise beeinflussen k{\"o}nnen. Dar{\"u}ber hinaus sind Mlh1G67R/G67R M{\"a}use, aufgrund der fehlenden Bindungsf{\"a}higkeit des MLH1G67R Proteins an die meiotischen Chromosomen im Pachyt{\"a}n Stadium, steril. Dies zeigt, dass die ATPase Aktivit{\"a}t von MLH1 f{\"u}r die Fertilit{\"a}t in S{\"a}ugern essentiell ist. Diese Untersuchungen belegen, dass die Mlh1G67R Mutation die biologischen MLH1 Funktionen differentiell mit einem eindeutigen Ph{\"a}notyp beeinflusst. Um die Rolle von MLH1 f{\"u}r die Lymphomagenese detaillierter untersuchen zu k{\"o}nnen, generierten wir ein neues Mausmodell mit einem konditionellen Mlh1 Allel (Mlh1flox/flox). Das Einkreuzen von transgenen EIIa-Cre Mausen in die Mlh1flox/flox Mauslinie f{\"u}hrte zur konstitutiven Inaktivierung von MLH1. Die resultierende Mlh1Δex4/Δex4 Mauslinie zeichnete sich durch MMR Defizienz und einen zu Mlh1-/- Tieren vergleichbaren Tumorpr{\"a}dispositions Ph{\"a}notyp aus. Zur T-Zell spezifischen MMR Inaktivierung kombinierten wir das Mlh1flox/flox Allel mit dem Lck-Cre Transgen. In den resultierenden Mlh1TΔex4/TΔex4 M{\"a}usen ist die MLH1 Inaktivierung auf doppelt positive und einzel positive Thymozyten und na{\"i}ve periphere TZellen beschr{\"a}nkt. Die Entwicklung von T-Zell Lymphomen in Mlh1TΔex4/TΔex4 M{\"a}usen ist im Vergleich zu Mlh1-/- M{\"a}usen signifikant reduziert, was eine wichtige, Lymphom supprimierende MMR Funktion in fr{\"u}hen Stadien der T-Zell Entwicklung oder in lymphoiden Vorl{\"a}uferzellen impliziert.},
  subject      = {Colonkrebs},
  language  = {de}
}
@article{ArdeltEbbingAdamsetal.2015,
  author    = {Ardelt, Peter U. and Ebbing, Jan and Adams, Fabian and Reiss, Cora and Arap, Wadih and Pasqualini, Renata and Bachmann, Alexander and Wetterauer, Ulrich and Riedmiller, Hubertus and Kneitz, Burkard},
  title     = {An anti-ubiquitin antibody response in transitional cell carcinoma of the urinary bladder},
  series = {PLoS ONE},
  volume    = {10},
  journal   = {PLoS ONE},
  number    = {3},
  doi       = {10.1371/journal.pone.0118646},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143711},
  pages     = {e0118646},
  year      = {2015},
  abstract  = {Background To use combinatorial epitope mapping ("fingerprinting") of the antibody response to identify targets of the humoral immune response in patients with transitional cell carcinoma (TCC) of the bladder. Methods A combinatorial random peptide library was screened on the circulating pool of immunoglobulins purified from an index patient with a high risk TCC (pTa high grade plus carcinoma in situ) to identify corresponding target antigens. A patient cohort was investigated for antibody titers against ubiquitin. Results We selected, isolated, and validated an immunogenic peptide motif from ubiquitin as a dominant epitope of the humoral response. Patients with TCC had significantly higher antibody titers against ubiquitin than healthy donors (p<0.007), prostate cancer patients (p<0.0007), and all patients without TCC taken together (p<0.0001). Titers from superficial tumors were not significantly different from muscle invasive tumors (p = 0.0929). For antibody response against ubiquitin, sensitivity for detection of TCC was 0.44, specificity 0.96, positive predictive value 0.96 and negative predictive value 0.41. No significant titer changes were observed during the standard BCG induction immunotherapy. Conclusions This is the first report to demonstrate an anti-ubiquitin antibody response in patients with TCC. Although sensitivity of antibody production was low, a high specificity and positive predictive value make ubiquitin an interesting candidate for further diagnostic and possibly immune modulating studies.},
  language  = {en}
}
@article{GambaryanSubramanianKehreretal.2016,
  author    = {Gambaryan, Stepan and Subramanian, Hariharan and Kehrer, Linda and Mindukshev, Igor and Sudnitsyna, Julia and Reiss, Cora and Rukoyatkina, Natalia and Friebe, Andreas and Sharina, Iraida and Martin, Emil and Walter, Ulrich},
  title     = {Erythrocytes do not activate purified and platelet soluble guanylate cyclases even in conditions favourable for NO synthesis},
  series = {Cell Communication and Signaling},
  volume    = {14},
  journal   = {Cell Communication and Signaling},
  number    = {16},
  doi       = {10.1186/s12964-016-0139-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-161223},
  year      = {2016},
  abstract  = {Background Direct interaction between Red blood cells (RBCs) and platelets is known for a long time. The bleeding time is prolonged in anemic patients independent of their platelet count and could be corrected by transfusion of RBCs, which indicates that RBCs play an important role in hemostasis and platelet activation. However, in the last few years, opposing mechanisms of platelet inhibition by RBCs derived nitric oxide (NO) were proposed. The aim of our study was to identify whether RBCs could produce NO and activate soluble guanylate cyclase (sGC) in platelets. Methods To test whether RBCs could activate sGC under different conditions (whole blood, under hypoxia, or even loaded with NO), we used our well-established and highly sensitive models of NO-dependent sGC activation in platelets and activation of purified sGC. The activation of sGC was monitored by detecting the phosphorylation of Vasodilator Stimulated Phosphoprotein (VASPS239) by flow cytometry and Western blot. ANOVA followed by Bonferroni's test and Student's t-test were used as appropriate. Results We show that in the whole blood, RBCs prevent NO-mediated inhibition of ADP and TRAP6-induced platelet activation. Likewise, coincubation of RBCs with platelets results in strong inhibition of NO-induced sGC activation. Under hypoxic conditions, incubation of RBCs with NO donor leads to Hb-NO formation which inhibits sGC activation in platelets. Similarly, RBCs inhibit activation of purified sGC, even under conditions optimal for RBC-mediated generation of NO from nitrite. Conclusions All our experiments demonstrate that RBCs act as strong NO scavengers and prevent NO-mediated inhibition of activated platelets. In all tested conditions, RBCs were not able to activate platelet or purified sGC.},
  language  = {en}
}